| 000 | 01766 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517171823.0 | ||
| 264 | 0 | _c20180521 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1791-3004 | ||
| 024 | 7 |
_a10.3892/mmr.2017.7215 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFan, Rui-Fang | |
| 245 | 0 | 0 |
_aPIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. _h[electronic resource] |
| 260 |
_bMolecular medicine reports _cOct 2017 |
||
| 300 |
_a4603-4612 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBenzylidene Compounds _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aGlycogen Synthase Kinase 3 beta _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aProtein Transport |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-pim-1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aThiazolidinediones _xpharmacology |
| 650 | 0 | 4 |
_abeta Catenin _xmetabolism |
| 700 | 1 | _aLu, Ying | |
| 700 | 1 | _aFang, Zhi-Gang | |
| 700 | 1 | _aGuo, Xiao-Yan | |
| 700 | 1 | _aChen, Yu-Xin | |
| 700 | 1 | _aXu, Yi-Chuan | |
| 700 | 1 | _aLei, Ya-Mei | |
| 700 | 1 | _aLiu, Ke-Fang | |
| 700 | 1 | _aLin, Dong-Jun | |
| 700 | 1 | _aLiu, Ling-Ling | |
| 700 | 1 | _aLiu, Xiang-Fu | |
| 773 | 0 |
_tMolecular medicine reports _gvol. 16 _gno. 4 _gp. 4603-4612 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3892/mmr.2017.7215 _zAvailable from publisher's website |
| 999 |
_c27505783 _d27505783 |
||